查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全基因及EXOME定序的全球市场:各用途，生物，各产品，附执行顾问指南 - D2C分析(2024年～2028年)
市场调查报告书
商品编码
1507971

全基因及EXOME定序的全球市场:各用途，生物，各产品，附执行顾问指南 - D2C分析(2024年～2028年)

Whole Genome and Exome Sequencing Markets. By Application, Organism and Product with Executive and Consultant Guides. Includes Direct to Consumer Analysis. 2024 to 2028
出版日期: | 出版商: Howe Sound Research | 英文 650 Pages | 商品交期: 最快1-2个工作天内

价格

本报告提供全球全基因及EXOME定序市场相关调查，提供市场概要，以及各用途，生物，各产品趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 市场指南

第2章 简介和市场定义

  • 该报告的全基因测序定义
  • 基因学革命
  • 市场定义
  • 调查手法
  • 观点：医疗保健和 IVD 产业
  • 基因组大小－与你想像的不同
  • 全球已安装的高通量定序设施列表
  • BASE-位置和联络资讯

第3章 市场概要

  • 市场参与企业完成不同的作用
    • 设备厂商
    • 独立型研究所(专门的/费解)
    • 独立型研究所(国内/地区)
    • 独立型实验室分析
    • 公立国立/地区研究所
    • 医院检验室
    • 临床检验室
    • DTC实验室
    • 定序实验室
    • 审核机关
  • 全基因排列分析- 市场，案例，考察
  • 产业结构

第4章 市场趋势

  • 成长促进因素
  • 成长限制要素
  • 定序设备

第5章 全基因及EXOME定序的最近的趋势

第6章 主要企业的简介

  • 10x Genomics, Inc.
  • 1928 Diagnostics
  • 23andME Inc.
  • Abbott Laboratories
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Agilent/Dako
  • Akonni Biosystems
  • Amoy Diagnostics Co., Ltd.
  • Ancestry.com LLC
  • Anchor Dx
  • ARUP Laboratories
  • BaseClear
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioMerieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Techne
  • C2i Genomics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Centogene
  • Circulogene
  • Clear Labs
  • Clinical Genomics
  • Complete Genomics, Inc.-A BGI Company
  • CosmosID
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Day Zero Diagnostics.
  • Diasorin S.p.A.
  • Element Biosciences
  • Element Biosciences
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Fabric Genomics
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fulgent Genetics
  • GE Global Research
  • Gencove
  • Genedrive
  • GeneDx Holdings
  • GeneFirst Ltd.
  • Genetron Holdings
  • Genewiz
  • Genomics England
  • Genomics Personalized Health(GPH)
  • GenomOncology
  • Genzyme Corporation
  • Grifols
  • Guardant Health
  • Guardiome
  • HeiScreen
  • Helix
  • Helix OpCo
  • Helomics
  • Hologic
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Lunglife AI Inc
  • Macrogen
  • MDNA Life SCIENCES, Inc.
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Biotech(Thermo Fisher)
  • Mesa Laboratories, Inc.
  • miR Scientific
  • MNG Labs
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • New England Biolabs, Inc.
  • Novogene Bioinformatics Technology Co., Ltd.
  • Omega Bioservices
  • Oncocyte
  • OncoDNA
  • OpGen
  • ORIG3N, Inc.
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • Panagene
  • Pathogenomix
  • PathoQuest S.A.
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Protagen Diagnostics
  • Qiagen
  • QuantuMDx
  • Regeneron Pharmaceuticals
  • Revvity
  • Roche Molecular Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • Singular Genomics
  • SkylineDx
  • Standard BioTools
  • Sure Genomics, Inc.
  • Sysmex
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Ultima Genomics
  • Ultima Genomics
  • Variantyx
  • Volition
  • Vyant Bio
  • Zymo Research Corp

第7章 全球全基因定序市场

  • 各国全球市场概要
  • 各用途全球市场概要
  • 各生物全球市场概要
  • 各产品全球市场概要

第8章 全球全基因测序市场- 各用途

  • 研究
  • 临床:人
  • 临床:人 - 迅速
  • 临床:肿瘤
  • 临床:病原体
  • D2C
  • 农业/其他

第9章 全球全基因测序市场- 生物

  • 人
  • 病原体
  • 其他

第10章 全球全基因测序市场- 各产品

  • 设备
  • 试剂
  • 分析
  • 软体以及其他

第11章 全基因定序的未来愿景

第12章 附录

OVERVIEW:

"Is Whole Genome Sequencing crossing the chasm? A new industry emerges with unprecedented growth..."

Will all newborns receive Whole Genome Sequencing at birth? How fast will Direct to Consumer Testing grow? What sequencing technology will take the lead? What's holding the industry back? Where are over 800 locations that have high throughput devices?

Our facts and support = Your success.

New consumers, new technologies, new specializations. In a situation reminiscent of the birth of the internet industry a wide range of well funded players are racing for market share on a truly global stage. The report forecasts the market size out five years. The report includes detailed breakouts for 14 countries and 5 regions.

Tumor Cell Sequencing? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities, and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

All report data is available in Excel format on request. Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1 Market Guides

  • 1.1 Whole Genome Sequencing Market-Strategic Situation Analysis
  • 1.2 Guide for Executives, Marketing, Sales and Business Development Staff
  • 1.3 Guide for Management Consultants and Investment Advisors

2 Introduction and Market Definition

  • 2.1 Whole Genome Sequencing Definition In This Report
    • 2.1.1 Whole and Exome Sequencing
    • 2.1.2 Research
    • 2.1.3 Clinical Human
    • 2.1.4 Clinical Human Rapid
    • 2.1.5 Clinical Tumor
    • 2.1.6 Clinical Pathogen
    • 2.1.7 Agri/Other
    • 2.1.8 Direct to Consumer
  • 2.2 The Genomics Revolution
  • 2.3 Market Definition
    • 2.3.1 Revenue Market Size
  • 2.4 Methodology
    • 2.4.1 Methodology
    • 2.4.2 Sources
    • 2.4.3 Authors
  • 2.5 Perspective: Healthcare and the IVD Industry
    • 2.5.1 Global Healthcare Spending
    • 2.5.2 Spending on Diagnostics
    • 2.5.3 Important Role of Insurance for Diagnostics
  • 2.6 Sizing the Genome - Not What You Think
    • 2.6.1 Cost, Price and Genome Size, Pricing Practice
  • 2.7 GLOBAL LISTING OF HIGH THROUGHPUT SEQUENCING ESTABLISHMENTS INSTALLED
  • BASE - Location & Contacts

3 Market Overview

  • 3.1 Market Participants Play Different Roles
    • 3.1.1 Instrument Manufacturer
    • 3.1.2 Independent lab specialized/esoteric
    • 3.1.3 Independent lab national/regional
    • 3.1.4 Independent lab analytical
    • 3.1.5 Public National/regional lab
    • 3.1.6 Hospital lab
    • 3.1.7 Physician lab
    • 3.1.8 DTC Lab
    • 3.1.9 Sequencing Labs
    • 3.1.10 Audit body
  • 3.2 Whole Genome Sequencing -Markets, Examples and Discussion
    • 3.2.1 Direct to Consumer - Two Approaches
      • 3.2.1.1 The New Age of Medical Information
      • 3.2.1.2 Dangers in DTC-WGS - Health Costs and Regulation
      • 3.2.1.3 Newborn and Prenatal - A Brave New World
      • 3.2.1.4 DTC - How Many Segments?
    • 3.2.2 Research Markets
      • 3.2.2.1 Research Funding and Capital Expense
      • 3.2.2.2 WGS Datasets Preferred
      • 3.2.2.3 Existing research repurposed
      • 3.2.2.4 Organism Wide Market
      • 3.2.2.5 Service Suppliers Respond
    • 3.2.3 Clinical - Understanding Germline and Somatic
      • 3.2.3.1 Somatic - Chasing Mutations and Pharmacogenomics
    • 3.2.4 Pathogen Testing
      • 3.2.4.1 The Hepatitis C Story
      • 3.2.4.2 Will the Microbiology Department Disappear?
    • 3.2.5 AgriBio - Big Business
      • 3.2.5.1 GMO is Here to Stay
      • 3.2.5.2 WGS Benefits and Risks
      • 3.2.5.3 The New Agriculture
  • 3.3 Industry Structure
    • 3.3.1 Hospital's Testing Share
    • 3.3.2 Economies of Scale
    • 3.3.3 Instrument Manufacturer Role
    • 3.3.4 Healthcare Industry Impacts - Still Struggling
      • 3.3.4.1 Can the Healthcare Industry Adapt?
      • 3.3.4.2 Genetic Counselling as an Industry
      • 3.3.4.3 WGES Adoption and Cannibalization
      • 3.3.4.4 The Meaning of Grail

4 Market Trends

  • 4.1 Factors Driving Growth
    • 4.1.1 Diagnostic Factors
    • 4.1.2 Interpreting the Code Otherwise
    • 4.1.3 Changes in Agriculture
    • 4.1.4 Fertility Technology Comes of Age
    • 4.1.5 Pathogen Challenges
  • 4.2 Factors Limiting Growth
    • 4.2.1 Increased Competition Lowers Price
    • 4.2.2 Lower Costs
    • 4.2.3 Healthcare Cost Concerns Curtail Growth
    • 4.2.4 Wellness has a downside
    • 4.2.5 GMO Opposition Movement
  • 4.3 Sequencing Instrumentation
    • 4.3.1 Instrumentation Tenacity
    • 4.3.2 Declining Cost Changes Industry Structure
    • 4.3.3 LISTING of CURRENT NGS INSTRUMENT SPECIFICATIONS
    • 4.3.4 Illumina
    • 4.3.5 ION
    • 4.3.6 Pacific Biosystems
    • 4.3.7 Roche 454
    • 4.3.8 SOLiD
    • 4.3.9 Oxford Nanopore
      • 4.3.9.1 What is Oxford Nanopore Sequencing?
      • 4.3.9.2 What can Oxford Nanopore Sequencingt be used for?
      • 4.3.9.3 Oxford Nanopore Products
    • 4.3.10 Long Reads - Further Segmentation
    • 4.3.11 Linked Reads
    • 4.3.12 Targeted Sequencing Adopts CRISPR
    • 4.3.13 New Sequencing Technologies
      • 4.3.13.1 RNAP sequencing
      • 4.3.13.2 In vitro virus high-throughput sequencing
      • 4.3.13.3 Tunnelling currents DNA sequencing
      • 4.3.13.4 Sequencing by hybridization
      • 4.3.13.5 Sequencing with mass spectrometry
      • 4.3.13.6 Microfluidic Sanger sequencing
      • 4.3.13.7 Microscopy-based techniques

5 WGES Recent Developments

  • 5.1 Recent Developments - Importance and How to Use This Section
    • 5.1.1 Importance of These Developments
    • 5.1.2 How to Use This Section
  • 5.2 Epic, GeneDx to broaden WGS potential
  • 5.3 Qiagen QiaSeq xHyb Mycobacterium Tuberculosis Panel
  • 5.4 WGS Uncovers Genetic causes of cerebral palsy
  • 5.5 Rapid WGS Use recommended for Intensive Care
  • 5.6 Quest and Ultima Genomics to Develop Tests
  • 5.7 WHO launches WGS Guide
  • 5.8 Myriad Genetics to Study MRD Testing
  • 5.9 Adela Developing Epigenetic Multi-Cancer Detection
  • 5.10 Epic Sciences Expanding Infrastructure for Liquid Biopsy Test
  • 5.11 Bionano Laboratories Announces New Prenatal Whole Genome Tests
  • 5.12 Myriad Genetics Plans Product Launches
  • 5.13 Genomics England, Aims to Sequence 100K Newborns
  • 5.14 Juno Diagnostics NIPT With At-Home Sample Collection
  • 5.15 Cardio Diagnostics Launches Genetic Cardio Risk Test
  • 5.16 Universal Genetic Testing in Breast Cancer Further Supported
  • 5.17 Aniling Gets CE-IVD Marks for Cancer Sequencing Tests
  • 5.18 MyOme Lands Investment for WGS
  • 5.19 GenomSys Gains CE Mark for New Genomic Analysis Software
  • 5.20 WGS Finds Lung Cancers Fall Into Molecular Subtypes
  • 5.21 Testing Distinguishes Benign Tumors From Precancerous Condition
  • 5.22 Plan to Sequence All Newborns in UK
  • 5.23 Clear Labs Raises $60M for Nanopore Sequencing
  • 5.24 Variantyx Expands Into Prenatal, Cancer Testing
  • 5.25 Whole-Genome Sequencing Aids Diagnosis in Stockholm
  • 5.26 Variantyx Raises $20M
  • 5.27 Nonacus WGS Service for SARS-CoV-2 Laboratories
  • 5.28 Center to Report Risk Scores in Clinical WGS
  • 5.29 Stanford Launches WGS for Cardiovascular Testing
  • 5.30 Illumina and NY Healthcare Partner on Clinical WGS
  • 5.31 Increased Adoption of WGS Needs Acceptance by Payors, Providers
  • 5.32 Veritas Intercontinental Completes Euro-5M Series B Financing Round
  • 5.33 M2GEN and Discovery Life Sciences in Bioinformatics Agreement
  • 5.34 Genomics England Adopts Quantum ActiveScale Object Storage
  • 5.35 GenomiQa, Icon Group to Validate Genomic Analysis Platform CapeDx
  • 5.36 NHS Wales Introduces WGS for Critically Ill Newborns
  • 5.37 Illumina Achieves EAU for NGS-Based SARS-CoV-2 Test
  • 5.38 C2i Genomics to Launch Trials for MRD Detection Tech
  • 5.39 Roche Acquires Sequencing Company Stratos Genomics
  • 5.40 UK COVID-19 Sequencing Consortium Launches
  • 5.41 Invitae Acquires Three Companies: YouScript, Genelex, Diploid
  • 5.42 Experience From Centralized Genomic Medicine Lab
  • 5.43 MGI to Enable $100 Human Genome
  • 5.44 Nebula Genomics offers $299 WGS
  • 5.45 Team to Study Campylobacter Omics
  • 5.46 Veritas Genetics Restarts US Business
  • 5.47 NEOGEN, Gencove partner to advance animal genomics

6 Profiles of Key Companies

  • 6.1 10x Genomics, Inc.
  • 6.2 1928 Diagnostics
  • 6.3 23andME Inc.
  • 6.4 Abbott Laboratories
  • 6.5 AccuraGen Inc.
  • 6.6 Adaptive Biotechnologies
  • 6.7 Admera Health, LLC
  • 6.8 Agilent/Dako
  • 6.9 Akonni Biosystems
  • 6.10 Amoy Diagnostics Co., Ltd.
  • 6.11 Ancestry.com LLC
  • 6.12 Anchor Dx
  • 6.13 ARUP Laboratories
  • 6.14 BaseClear
  • 6.15 Baylor Miraca Genetics Laboratories
  • 6.16 Beckman Coulter Diagnostics
  • 6.17 Becton, Dickinson and Company
  • 6.18 BGI Genomics Co. Ltd
  • 6.19 Bioarray Genetics
  • 6.20 Biocept, Inc.
  • 6.21 Biodesix Inc.
  • 6.22 BioFluidica
  • 6.23 BioGenex
  • 6.24 Biolidics Ltd
  • 6.25 bioMerieux Diagnostics
  • 6.26 Bioneer Corporation
  • 6.27 Bio-Rad Laboratories, Inc
  • 6.28 Bio-Techne
  • 6.29 C2i Genomics
  • 6.30 Caris Molecular Diagnostics
  • 6.31 CellMax Life
  • 6.32 Centogene
  • 6.33 Circulogene
  • 6.34 Clear Labs
  • 6.35 Clinical Genomics
  • 6.36 Complete Genomics, Inc. - A BGI Company
  • 6.37 CosmosID
  • 6.38 Dante Labs
  • 6.39 Datar Cancer Genetics Limited
  • 6.40 Day Zero Diagnostics.
  • 6.41 Diasorin S.p.A.
  • 6.42 Element Biosciences
  • 6.43 Element Biosciences
  • 6.44 Epic Sciences
  • 6.45 Epigenomics AG
  • 6.46 Eurofins Scientific
  • 6.47 Excellerate Bioscience
  • 6.48 Fabric Genomics
  • 6.49 Freenome
  • 6.50 FUJIFILM Wako Diagnostics
  • 6.51 Fulgent Genetics
  • 6.52 GE Global Research
  • 6.53 Gencove
  • 6.54 Genedrive
  • 6.55 GeneDx Holdings
  • 6.56 GeneFirst Ltd.
  • 6.57 Genetron Holdings
  • 6.58 Genewiz
  • 6.59 Genomics England
  • 6.60 Genomics Personalized Health (GPH)
  • 6.61 GenomOncology
  • 6.62 Genzyme Corporation
  • 6.63 Grifols
  • 6.64 Guardant Health
  • 6.65 Guardiome
  • 6.66 HeiScreen
  • 6.67 Helix
  • 6.68 Helix OpCo
  • 6.69 Helomics
  • 6.70 Hologic
  • 6.71 HTG Molecular Diagnostics
  • 6.72 Human Longevity, Inc.
  • 6.73 iCellate
  • 6.74 Illumina
  • 6.75 Incell Dx
  • 6.76 Inivata
  • 6.77 Invitae Corporation
  • 6.78 Invivoscribe
  • 6.79 Karius
  • 6.80 Lunglife AI Inc
  • 6.81 Macrogen
  • 6.82 MDNA Life SCIENCES, Inc.
  • 6.83 MDx Health
  • 6.84 Medgenome
  • 6.85 Meridian Bioscience
  • 6.86 Mesa Biotech (Thermo Fisher)
  • 6.87 Mesa Laboratories, Inc.
  • 6.88 miR Scientific
  • 6.89 MNG Labs
  • 6.90 NantHealth, Inc.
  • 6.91 Natera
  • 6.92 Nebula Genomics
  • 6.93 NeoGenomics
  • 6.94 New England Biolabs, Inc.
  • 6.95 Novogene Bioinformatics Technology Co., Ltd.
  • 6.96 Omega Bioservices
  • 6.97 Oncocyte
  • 6.98 OncoDNA
  • 6.99 OpGen
  • 6.100 ORIG3N, Inc.
  • 6.101 Origene Technologies
  • 6.102 Oxford Nanopore Technologies
  • 6.103 Pacific Biosciences
  • 6.104 Panagene
  • 6.105 Pathogenomix
  • 6.106 PathoQuest S.A.
  • 6.107 Personal Genome Diagnostics
  • 6.108 Personalis
  • 6.109 Precipio
  • 6.110 PrecisionMed
  • 6.111 Promega
  • 6.112 Protagen Diagnostics
  • 6.113 Qiagen
  • 6.114 QuantuMDx
  • 6.115 Regeneron Pharmaceuticals
  • 6.116 Revvity
  • 6.117 Roche Molecular Diagnostics
  • 6.118 Roswell Biotechnologies
  • 6.119 Seegene
  • 6.120 Sequencing.com
  • 6.121 Siemens Healthineers
  • 6.122 simfo GmbH
  • 6.123 Singlera Genomics Inc.
  • 6.124 Singular Genomics
  • 6.125 SkylineDx
  • 6.126 Standard BioTools
  • 6.127 Sure Genomics, Inc.
  • 6.128 Sysmex
  • 6.129 Sysmex Inostics
  • 6.130 Tempus Labs, Inc.
  • 6.131 Thermo Fisher Scientific Inc.
  • 6.132 Ultima Genomics
  • 6.133 Ultima Genomics
  • 6.134 Variantyx
  • 6.135 Volition
  • 6.136 Vyant Bio
  • 6.137 Zymo Research Corp

7 The Global Market for Whole Genome Sequencing

  • 7.1 Global Market Overview by Country
    • 7.1.1 Table - Global Market by Country
    • 7.1.2 Chart-Global Market by Country
  • 7.2 Global Market by Application-Overview
    • 7.2.1 Table - Global Market by Application
    • 7.2.2 Chart - Global Market by Application - Base/Final Year Comparison
    • 7.2.3 Chart - Global Market by Application - Base Year
    • 7.2.4 Chart - Global Market by Application - Final Year
    • 7.2.5 Chart - Global Market by Application - Share by Year
    • 7.2.6 Chart - Global Market by Application - Segment Growth
  • 7.3 Global Market by Organism-Overview
    • 7.3.1 Table - Global Market by Organism
    • 7.3.2 Chart - Global Market by Organism - Base/Final Year Comparison
    • 7.3.3 Chart - Global Market by Organism - Base Year
    • 7.3.4 Chart - Global Market by Organism - Final Year
    • 7.3.5 Chart - Global Market by Organism - Share by Year
    • 7.3.6 Chart - Global Market by Organism - Segment Growth
  • 7.4 Global Market by Product-Overview
    • 7.4.1 Table - Global Market by Product
    • 7.4.2 Chart - Global Market by Product - Base/Final Year Comparison
    • 7.4.3 Chart - Global Market by Product - Base Year
    • 7.4.4 Chart - Global Market by Product - Final Year
    • 7.4.5 Chart - Global Market by Product - Share by Year
    • 7.4.6 Chart - Global Market by Product - Segment Growth

8 Global Whole Genome Sequencing Markets - by Application

  • 8.1 Research
    • 8.1.1 Table Research - by Country
    • 8.1.2 Chart-Research Growth
  • 8.2 Clinical Human
    • 8.2.1 Table Clinical Human - by Country
    • 8.2.2 Chart-Clinical Human Growth
  • 8.3 Clinical Human Rapid
    • 8.3.1 Table Clinical Human Rapid - by Country
    • 8.3.2 Chart-Clinical Human Rapid Growth
  • 8.4 Clinical Tumor
    • 8.4.1 Table Clinical Tumor - by Country
    • 8.4.2 Chart-Clinical Tumor Growth
  • 8.5 Clinical Pathogen
    • 8.5.1 Table Clinical Pathogen - by Country
    • 8.5.2 Chart-Clinical Pathogen Growth
  • 8.6 Direct to Consumer
    • 8.6.1 Table Direct to Consumer - by Country
    • 8.6.2 Chart - Direct to Consumer Growth
  • 8.7 Agriculture/Other
    • 8.7.1 Table Agriculture/Other - by Country
    • 8.7.2 Chart - Agriculture/Other Growth

9 Global Whole Genome Sequencing Markets - by Organism

  • 9.1 Human
    • 9.1.1 Table Human - by Country
    • 9.1.2 Chart-Human Growth
  • 9.2 Pathogen
    • 9.2.1 Table Pathogen - by Country
    • 9.2.2 Chart-Pathogen Growth
  • 9.3 Other Organism
    • 9.3.1 Table Other Organism - by Country
    • 9.3.2 Chart-Other Organism Growth

10 Global Whole Genome Sequencing Markets - by Product

  • 10.1 Instruments
    • 10.1.1 Table Instruments - by Country
    • 10.1.2 Chart-Instruments Growth
  • 10.2 Reagents
    • 10.2.1 Table Reagents - by Country
    • 10.2.2 Chart-Reagent Growth
  • 10.3 Analysis
    • 10.3.1 Table Analysis - by Country
    • 10.3.2 Chart-Analysis Growth
  • 10.4 Software & Other
    • 10.4.1 Table Software & Other - by Country
    • 10.4.2 Chart - Software & Other Growth

11 Vision of the Future of Whole Genome Sequencing

12 Appendices

  • 12.1 United States Medicare System: Laboratory Fees Schedule
  • 12.2 The Most Used IVD Assays
  • 12.3 The Highest Grossing Assays
  • 12.4 The Whole Genome Sequence of SARS-CoV-2

Table of Tables

  • Table 1 The Base Pairs
  • Table 2 Most Common Traditional Genetic Disorders
  • Table 3 List of GLOBAL SEQUENCING LOCATIONS
  • Table 4 Market Players by Type
  • Table 5 The Different Markets for Whole Genome Sequencing
  • Table 6 DTC Sub Segments
  • Table 7 Roles of WGS in AgriBio
  • Table 8 The Factors Driving Growth
  • Table 9 Factors Limiting Growth
  • Table 10-Listing of Current NGS Instrument Specifications
  • Table 11 Six New Sequencing Technologies
  • Table 12-Global Market by Region
  • Table 13 Global Market by Application
  • Table 14 Global Market by Organism
  • Table 15 Global Market by Product
  • Table 16 Research by Country
  • Table 17 Clinical Human by Country
  • Table 18 Clinical Human Rapid by Country
  • Table 19 Clinical Tumor by Country
  • Table 20 Clinical Pathogen by Country
  • Table 21 Direct to Consumer by Country
  • Table 22 Agriculture/Other by Country
  • Table 23 Human by Country
  • Table 24 Pathogen by Country
  • Table 25 Other Organism by Country
  • Table 26 Instruments by Country
  • Table 27 Reagents by Country
  • Table 28 Analysis by Country
  • Table 29 Software & Other by Country
  • Table 30 Clinical Lab Fee Schedule
  • Table 31 The Most Common Assays
  • Table 32 Largest Revenue Assays

Table of Figures

  • Figure 1 Global Healthcare Spending
  • Figure 2 The Lab Test Pie
  • Figure 3 Size of Genome for Various Species
  • Figure 4-Cost To Sequence a Human Genome
  • Figure 5 Base Year Country Market Share Chart
  • Figure 6 Global Market by Application-Base vs. Final Year
  • Figure 7 Global Market by Application Base Year
  • Figure 8 Global Market by Application Final Year
  • Figure 9 Application Type Share by Year
  • Figure 10 by Application Segment Growth
  • Figure 11 by Organism - Base vs. Final Year
  • Figure 12 by Organism Market Base Year
  • Figure 13 by Organism Market Final Year
  • Figure 14 by Organism Share by Year
  • Figure 15 by Organism Segment Growth
  • Figure 16 by Product - Base vs. Final Year
  • Figure 17 by Product Market Base Year
  • Figure 18 by Product Market Final Year
  • Figure 19 by Product Share by Year
  • Figure 20 by Product Segment Growth
  • Figure 21 Research Growth
  • Figure 22 Clinical Human Growth
  • Figure 23 Clinical Human Growth
  • Figure 24 Clinical Tumor Growth
  • Figure 25 Clinical Pathogen Growth
  • Figure 26 Direct to Consumer Growth
  • Figure 27 Agriculture/Other Growth
  • Figure 28 Human Growth
  • Figure 29 Pathogen Growth
  • Figure 30 Other Organism Growth
  • Figure 31 Instruments Growth
  • Figure 32 Reagent Growth
  • Figure 33 Analysis Growth
  • Figure 34 Software & Other Growth